**[Name of Offeror]**

[Address of Offeror]

DUNS #: [DUNS #]

CAGE code: [CAGE code]

**[Title of White Paper]**

**[Specific Requirement addressed in White Paper]**

[Offeror] certifies that it ( ) is or ( ) is not a Non-Profit Research Institution or Non-Traditional Defense Contractor, as defined in 10 U.S. Code § 2371b.

*As defined in 15 U.S.C. 3703, a nonprofit institution means an organization owned and operated exclusively for scientific or educational purposes, no part of the net earnings of which insures to the benefit of any private shareholder or individual; and includes federally funded research and development centers, as identified by the National Scientific Foundation in accordance with the government wide Federal Acquisition Regulation issued in accordance with section 1303(a)(1) of title 41 (or any successor regulation thereto).*

*A Nontraditional Defense Contractor is an entity that is not currently performing and has not performed, for at least the one-year period preceding the solicitation of sources by DoD for the procurement or transaction, any contract or subcontract for the DoD that is subject to full coverage under the cost accounting standards prescribed pursuant to section 1502 of title 41 and the regulations implementing such section (see 10 U.S.C. 2302(9)).*

[Offeror] Objective Area of Prototype

( ) Diagnostics/Monitoring ( ) Surveillance ( ) Information Systems Technologies

( ) Therapeutics ( ) Prophylactics ( ) Clinical Trials

[A proprietary data disclosure statement, if proprietary data is included. Sample:

This White Paper includes data that shall not be disclosed outside Advanced Technology International, ATI (the MCDC Management Firm) and the Government and shall not be duplicated, used, or disclosed, in whole or in part, for any purpose other than to review this White Paper. If, however, an agreement is awarded in connection with the submission of this data, the MCDC Management Firm and the Government shall have the right to duplicate, use, or disclose these data to the extent provided in the resulting agreement. This restriction does not limit the MCDC Management Firm and the Government's right to use the information contained in these data if they are obtained from another source without restriction. The data subject to this restriction is (clearly identify) and contained on pages (insert page numbers).]

 **[Title of White Paper]**

# **SECTION 1: TECHNICAL**

## Section 1.1: Technical Approach

* Describe the core of the intended approach, as it addresses the requirements listed above relative to combating the novel Coronavirus (2019-nCoV) pandemic. Address enhancing the mission effectiveness of military personnel, first responders, and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the armed forces, as well as the general public. Provide technical detail and analysis to support the approach being proposed. This includes identifying what technical baseline from which your initiative will begin (including work you have already done).
* Define the scope of the effort, including the proposed technology and a summary of the technical/process issues being addressed.
* Explain if the effort is a complete solution to the requirement, or some portion thereof.
* If applicable, identify any other Government solicitations or requests for information where the offeror has proposed this solution.
* If proposing a “new and creative” solution, develop and analyze the following:
	+ Results of/evidence of the current state of the art and how your approach compares to other possible approaches.
	+ Current limitations of the general technology area/process being addressed.
	+ Connections to ongoing initiatives in the general technology area/process being addressed.

## Section 1.2: Test/Evaluation

* Explain briefly, how the prototype will be tested, demonstrated and/or evaluated for technical feasibility, manufacturing feasibility and/or military utility, including where and by whom that testing will take place.
* Pay close attention to whatever the key technology or enhancement is.

## Section 1.3: Schedule

* Propose a notional schedule and period of performance (detailed Gantt chart not required).

## Section 1.4: Regulatory Strategy

* The Offeror shall, briefly, describe its regulatory strategy to achieve project objectives, including Emergency Use Authorization (EUA). The description shall address adherence to Food and Drug Administration (FDA) quality requirements and/or any other certifications.

# **SECTION 2: ESTIMATE**

## Section 2.1: Estimate Summary

* Provide a high-level cost estimate for the proposed solution (Rough Order of Magnitude – ROM).